1-6 of 6
Matthew Sugidono
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Free
Anne-Ségolène Cottereau, Alex Herrera, Hervé Tilly, Gilles Salles, Loïc Chartier, Matthew Sugidono, Skander Jemaa, Richard Carano, Connie Lee Batlevi, Greg Hapgood, Georg Lenz, Franck Morschhauser
Journal: Blood
Blood (2025) 146 (Supplement 1): 5329.
https://doi.org/10.1182/blood-2025-5329
Published: 2025
Journal Articles

A single-cell co-expression score of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin in the POLARIX trial

Free
Shruti Sridhar, Will Harris, Chartsiam Tipgomut, Qiang Pan-Hammarstrom, Gilles Salles, Alex Herrera, Marek Trneny, Franck Morschhauser, Connie Lee Batlevi, Matthew Sugidono, Yanwen Jiang, Georg Lenz, Anand Devaprasath Jeyasekharan
Journal: Blood
Blood (2025) 146 (Supplement 1): 3522.
https://doi.org/10.1182/blood-2025-3522
Published: 2025
Journal Articles

Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities

Free
James Godfrey, Sravya Tumuluru, Alan Cooper, Gilles Salles, Marek Trneny, Georg Lenz, Franck Morschhauser, Fabrice Jardin, Will Harris, Sandhya Balasubramanian, Matthew Sugidono, Connie Lee Batlevi, Yanwen Jiang, Justin Kline, Alex Herrera
Journal: Blood
Blood (2025) 146 (Supplement 1): 49.
https://doi.org/10.1182/blood-2025-49
Published: 2025
Journal Articles

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Open Access
Carrie Thompson, Marek Trněný, Franck Morschhauser, Gilles A. Salles, Patrick M. M. Reagan, Mark Hertzberg, Huilai Zhang, Catherine Thieblemont, Bei Hu, Gustavo Fonseca, Won Seog Seog Kim, Maurizio Martelli, Amitkumar Mehta, Avrita Singh, Mark Yan, Jamie Hirata, Matthew Sugidono, Calvin Lee, MD, Jeff P. Sharman, Neha Mehta-Shah, Christopher R. Flowers, Hervé Tilly, Neil Chua, Olivier Casasnovas, Fiona Miall, Tae Min Min Kim, Xavier Cheng-Hong Tsai, Sunita D. Nasta, Seung Tae Lee, Jonathan W. Friedberg
Journal: Blood
Blood blood.2025028848.
https://doi.org/10.1182/blood.2025028848
Published: 2025
Journal Articles

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Free
Gilles Salles, Franck Morschhauser, Laurie H. Sehn, Alex F. Herrera, Jonathan W. Friedberg, Marek Trněný, Georg Lenz, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Graham P. Collins, Yuqin Song, Antonio Pinto, Shinya Rai, Koji Izutsu, Calvin Lee, Saibah Chohan, Matthew Sugidono, Yanwen Jiang, Connie Lee Batlevi, Mark Yan, Jamie Hirata, Hervé Tilly, Christopher R. Flowers
Journal: Blood
Blood (2024) 144 (Supplement 1): 469.
https://doi.org/10.1182/blood-2024-197938
Published: 2024
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Free
Jonathan W. Friedberg, Carrie A. Thompson, Marek Trněný, Franck Morschhauser, Gilles Salles, Patrick M. Reagan, Mark Hertzberg, Piotr Smolewski, Huilai Zhang, Catherine Thieblemont, Bei Hu, Gustavo Fonseca, Won-Seog Kim, Maurizio Martelli, Amitkumar Mehta, Avrita Campinha-Bacote, Mark Yan, Jamie Hirata, Matthew Sugidono, Calvin Lee, Jeff P. Sharman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6623–6626.
https://doi.org/10.1182/blood-2022-157761
Published: 2022